Trial Profile
A Phase 1, Open-Label, Absolute Bioavailability Study of Vemurafenib in Patients With BRAF^V600 Mutation-Positive Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Vemurafenib (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Roche
- 15 Jun 2017 Status changed from recruiting to completed.
- 01 Jul 2016 Planned End Date changed from 1 Jan 2017 to 1 Apr 2017.
- 01 Jul 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Apr 2017.